Farallon Capital Management’s Sage Therapeutics SAGE Stock Holding History

Farallon Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42,800	Closed	-$390K	–	158
2025 Q2	$390K	Hold	42,800	–	–	﹤0.01%	99
2025 Q1	$340K	Hold	42,800	–	–	﹤0.01%	104
2024 Q4	$232K	Hold	42,800	–	–	﹤0.01%	121
2024 Q3	$309K	Hold	42,800	–	–	﹤0.01%	121
2024 Q2	$465K	Hold	42,800	–	–	﹤0.01%	111
2024 Q1	$802K	Hold	42,800	–	–	﹤0.01%	123
2023 Q4	$927K	Hold	42,800	–	–	﹤0.01%	108
2023 Q3	$881K	Buy	+42,800	New	+$1.24M	﹤0.01%	113
2021 Q2	–	Sell	-345,000	Closed	-$25.8M	–	310
2021 Q1	$25.8M	Sell	345,000 -705,000	-67%	-$57.8M	0.13%	94
2020 Q4	$90.8M	Hold	1,050,000	–	–	0.55%	48
2020 Q3	$64.2M	Buy	1,050,000 +200,000	+24%	+$10.1M	0.44%	57
2020 Q2	$35.3M	Buy	850,000 +175,000	+26%	+$6.35M	0.28%	67
2020 Q1	$19.4M	Buy	675,000 +175,000	+35%	+$10.1M	0.17%	69
2019 Q4	$36.1M	Buy	500,000 +127,200	+34%	+$15.6M	0.24%	65
2019 Q3	$52.3M	Sell	372,800 -127,200	-25%	-$21.3M	0.4%	49
2019 Q2	$91.5M	Sell	500,000 -100,000	-17%	-$17.1M	0.6%	39
2019 Q1	$95.4M	Buy	600,000 +200,000	+50%	+$29M	0.72%	39
2018 Q4	$38.3M	Sell	400,000 -225,000	-36%	-$25.7M	0.28%	54
2018 Q3	$88.3M	Hold	625,000	–	–	0.52%	37
2018 Q2	$97.8M	Buy	625,000 +180,000	+40%	+$28.3M	0.6%	37
2018 Q1	$71.7M	Buy	445,000 +45,000	+11%	+$7.64M	0.5%	42
2017 Q4	$65.9M	Buy	400,000 +156,500	+64%	+$15.2M	0.54%	37
2017 Q3	$15.2M	Buy	243,500 +143,500	+144%	+$11.3M	0.13%	63
2017 Q2	$7.96M	Buy	+100,000	New	+$7.23M	0.08%	71

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's SAGE Position: Q3 2025 in Review

Farallon Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 42,800 shares — an estimated $390K sold.

Farallon Capital Management first reported a position in SAGE in Q2 2017 and held it in 24 quarters. The position peaked at $97.8M in Q2 2018. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Farallon Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Farallon Capital Management sold 42,800 Sage Therapeutics shares in Q3 2025, an estimated $390K.
Farallon Capital Management first reported a position in Sage Therapeutics in Q2 2017 and held it in 24 quarters.
Farallon Capital Management's Sage Therapeutics position peaked at $97.8M in Q2 2018.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Farallon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.